BackCorbus Pharmaceuticals Holdings Overview
Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Target Price

See Corbus Pharmaceuticals Holdings's analyst price targets ($34) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$6.13

Average Target Price

$34.00454.6% upside

2 analysts in the last 4 months

High: $35 | Low: $33

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-26H.C. Wainwright$35471% upsideOpen
2026-08-13Mizuho SecuritiesGraig Suvannavejh$33438.3% upsideOpen
2026-05-22Mizuho SecuritiesGraig Suvannavejh$44617.8% upsideOpen
2026-05-12JefferiesMaury Raycroft$33438.3% upsideOpen
2025-10-29Mizuho Securities$39536.2% upsideOpen
2025-10-20Piper Sandler$51732% upsideOpen
2025-10-20H.C. Wainwright$40552.5% upsideOpen
2024-12-02Piper SandlerBiren Amin$35471% upsideOpen
2024-10-21OppenheimerJeff Jones$60878.8% upsideOpen
2024-09-20B.Riley FinancialKalpit Patel$40552.5% upsideOpen
2024-09-13Mizuho SecuritiesGraig Suvannavejh$741107.2% upsideOpen
2024-08-07OppenheimerJeff Jones$881335.6% upsideOpen
2024-07-22H.C. WainwrightAndres Maldonado$801205.1% upsideOpen
2024-06-11RBC CapitalBrian Abrahams$821237.7% upsideOpen
2024-06-03OppenheimerJeff Jones$801205.1% upsideOpen
2024-05-20RBC CapitalBrian Abrahams$771156.1% upsideOpen
2024-03-06JefferiesMaury Raycroft$46650.4% upsideOpen

Corbus Pharmaceuticals Holdings (CRBP) FAQ

Corbus Pharmaceuticals Holdings posts a target price of $34. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $34 for CRBP means covering analysts, on average, see the stock 454.6% upside of $6.13 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for CRBP's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Corbus Pharmaceuticals Holdings's other metric pages and overview cover the third.

Judging Corbus Pharmaceuticals Holdings against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $34 here, then scan peer and history charts to see if the gap is persistent.